Neurocrine biosciences presents new kinect® 4 post-hoc analysis demonstrating rapid and sustained therapeutic efficacy of ingrezza® (valbenazine) 40 mg capsules

Continuous treatment with ingrezza 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous treatment with ingrezza 40 mg achieved a ≥50% improvement in the abnormal involuntary movement scale total score ingrezza is the only vesicular monoamine transporter 2 (vmat2) inhibitor that allows patients to start immediately at a therapeutic dose without required titration san diego , oct. 17, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the presentation of a new post-hoc analysis from the phase 3, open-label kinect® 4 study, demonstrating that patients treated continuously for 48 weeks with the 40 mg dose of once-daily ingrezza® (valbenazine) capsules experienced clinically meaningful improvements in tardive dyskinesia symptoms. findings will be presented at the american psychiatric nurses association 39th annual conference, taking place october 15-18 in new orleans.
NBIX Ratings Summary
NBIX Quant Ranking